Preclinical News and Research

RSS

Phase I trial shows promise: Brain stimulation spurs upper-extremity recovery in stroke patients

Researchers performed an open-label phase I trial.

18 Aug 2023

New drug candidate nearly doubles survival for patients with aggressive childhood brain tumors

For the first time, researchers have found a potential drug candidate that improved outcomes for patients with a type of childhood brain tumor for which there are no effective treatments.

17 Aug 2023

Researchers receive DoD grant to target chemotherapy resistance in pancreatic cancer

Researchers with Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have been awarded a grant from the U.S. Department of Defense (DoD)'s Congressionally Directed Medical Research Program to target chemotherapy resistance in pancreatic cancer.

17 Aug 2023

Deep brain stimulation shows promise for post-stroke rehabilitation

A first-in-human trial of deep brain stimulation (DBS) for post-stroke rehabilitation patients by Cleveland Clinic researchers has shown that using DBS to target the dentate nucleus – which regulates fine-control of voluntary movements, cognition, language, and sensory functions in the brain – is safe and feasible.

14 Aug 2023

Unveiling α1-AR secrets: breakthrough structures and targeted drug design

Researchers explored the structural basis of agonist specificity of α1A-adrenergic receptors (α1-ARs).

14 Aug 2023

Genetically diverse mice reveal key differences in innate immune responses to SARS-CoV-2

Researchers at The Jackson Laboratory have created a panel of genetically diverse mice that accurately model the highly variable human response to SARS-CoV-2 infection.

11 Aug 2023

A drug for heart conditions improves efficacy of melanoma therapies

A collaborative study undertaken by the Navarrabiomed Biomedical Research Center (Pamplona, Navarre), the Institute of Neurosciences CSIC-UMH (Sant Joan d'Alacant, Valencian Community) and IRB Barcelona (Barcelona, Catalonia) shows that the administration of ranolazine, a drug currently used to treat heart conditions, improves the efficacy of current therapies for melanoma, in mouse models of this disease.

10 Aug 2023

Ovarian cancer patients enrolled in first-in-human trial of CAR T cell therapy

Recently published preclinical data by City of Hope scientists shows the immunotherapy is effective. Advanced ovarian cancer patients are now being enrolled in a Phase 1 first-in-human trial.

10 Aug 2023

New gene-editing tool helps to study single-base mutations in cancer

A change in just one letter in the code that makes up a cancer-causing gene can significantly affect how aggressive a tumor is or how well a patient with cancer responds to a particular therapy.

10 Aug 2023

Scientists develop "universal pan-mammalian clock" to accurately estimate age in mammals

Scientists at UCLA David Geffen School of Medicine and UCLA Health led an international research team that published two articles detailing changes in DNA – changes that researchers found are shared by humans and other mammals throughout history and are associated with life span and numerous other traits.

10 Aug 2023

Experimental drug can reduce symptoms of inflammatory bowel disease in pre-clinical models

A new study of mice and lab-grown human colon "organoids" indicates that an experimental drug developed by Johns Hopkins Medicine researchers can substantially reduce symptoms of inflammatory bowel disease (IBD) in pre-clinical models.

10 Aug 2023

MaxCyte and Vittoria Biotherapeutics sign strategic platform license to advance next generation cellular therapies

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, and Vittoria Biotherapeutics (Vittoria), a leading edge, gene-edited cell therapeutics company with novel platform technologies poised to develop a pipeline of highly differentiated cellular therapies for both oncology and immunology indications, today announced the signing of a strategic platform license (SPL) of MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to Vittoria Biotherapeutics.

From MaxCyte, Inc. 10 Aug 2023

Stem cell transplants may be a promising therapeutic against Alzheimer's, study shows

In the ongoing search for a cure for Alzheimer's disease, a burgeoning branch of medicine is bringing new hope. Stem cell therapies are already being used to treat various cancers and disorders of the blood and immune system.

9 Aug 2023

Duke researchers develop potent antibiotic against drug-resistant superbugs

A scientific journey decades in the making at Duke University has found a new antibiotic strategy to defeat gram-negative bacteria like Salmonella, Pseudomonas and E. coli, the culprits in many urinary tract infections (UTIs).

9 Aug 2023

CDK9 inhibitors: A promising new treatment for hematological malignancies

A new research perspective was published in Oncotarget's Volume 14 on August 7, 2023, entitled, "CDK9 INHIBITORS: a promising combination partner in the treatment of hematological malignancies."

9 Aug 2023

GABA transfer between skin cells promotes melanoma initiation

The transfer of a neurotransmitter from one type of skin cell to another (melanocytes to keratinocytes) altered electrical activity and promoted melanoma initiation in preclinical models, according to results published in Cancer Discovery, a journal of the American Association for Cancer Research.

9 Aug 2023

New treatment approach shows promise in reversing hormone resistance in breast cancer

A collaborative study between LSU Health New Orleans School of Medicine, the University of Rochester and Cellestia Biotech AG, a biopharmaceutical company headquartered in Basel, Switzerland, provides compelling evidence that combining an investigational oral drug with standard-of-care medications reverts hormone resistance and increases Rx effectiveness in experimental models of estrogen-receptor positive (ER+) and triple-negative breast cancers (TNBC), respectively.

9 Aug 2023

Preclinical News and Research

Phase I trial shows promise: Brain stimulation spurs upper-extremity recovery in stroke patients

New drug candidate nearly doubles survival for patients with aggressive childhood brain tumors

Researchers receive DoD grant to target chemotherapy resistance in pancreatic cancer

Deep brain stimulation shows promise for post-stroke rehabilitation

Unveiling α1-AR secrets: breakthrough structures and targeted drug design

Genetically diverse mice reveal key differences in innate immune responses to SARS-CoV-2

A drug for heart conditions improves efficacy of melanoma therapies

Ovarian cancer patients enrolled in first-in-human trial of CAR T cell therapy

New gene-editing tool helps to study single-base mutations in cancer

Scientists develop "universal pan-mammalian clock" to accurately estimate age in mammals

Experimental drug can reduce symptoms of inflammatory bowel disease in pre-clinical models

MaxCyte and Vittoria Biotherapeutics sign strategic platform license to advance next generation cellular therapies

Stem cell transplants may be a promising therapeutic against Alzheimer's, study shows

Duke researchers develop potent antibiotic against drug-resistant superbugs

CDK9 inhibitors: A promising new treatment for hematological malignancies

GABA transfer between skin cells promotes melanoma initiation

New treatment approach shows promise in reversing hormone resistance in breast cancer

Researchers design a probiotic to suppress autoimmunity in the brain

Are mushrooms an effective early dietary intervention for Alzheimer’s Disease?

The impact of epigenetic features on breast cancer treatment and outcomes

Event guide: 4th LNP Formulation & Process Development Summit eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics